ArticleIndian journal of dermatology2008
Adverse cutaneous drug reaction.
Article in Indian journal of dermatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 149 citations in OpenAlex.
- Web application for assisting non-dermatology physicians in learning and managing patients with common cutaneous adverse drug reactions: a multicenter randomized controlled trial.Annals of medicine · 2024Trial
- A Seven-Year Retrospective Study on the Epidemiology of Cutaneous Adverse Drug Reactions in Hospitalized Patients From Southern Iran: A Cross-Sectional Study.Health science reports · 2026Article
- Levocetirizine-induced paradoxical fixed drug eruption: A case report with causality assessment.Indian journal of pharmacology · 2026Article
- Inhibition of Inflammation by an Air-Based No-Ozone Cold Plasma in TNF-α-Induced Human Keratinocytes: An In Vitro Study.Current issues in molecular biology · 2026Article
- Article
- A Rare, Cephalosporin-induced Rash: Acute Generalized Exanthematous Pustulosis.Journal of community hospital internal medicine perspectives · 2025Article
- Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.Journal of clinical medicine · 2024Review
- Co-Trimoxazole-Induced Toxic Epidermal Necrolysis: A Case Report From Nepal.Clinical case reports · 2024Article
- Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Prospective Analysis of Cutaneous Adverse Drug Reactions Encountered in a Tertiary Care Hospital.Cureus · 2024Article
- Novel Strategy in the Detection of Adverse Cutaneous Drug Reactions: A Case Series Study.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- The Assessment of Meloxicam Phototoxicity in Human Normal Skin Cells: In Vitro Studies on Dermal Fibroblasts and Epidermal Melanocytes.Molecules (Basel, Switzerland) · 2022Article
- Misdiagnosis of Human Herpes Virus-8-Associated Kaposi's Sarcoma as Adverse Drug Eruptions.Archives of plastic surgery · 2022Article
- Antibiotic-Related Adverse Drug Reactions in Patients Treated on the Dermatology Ward of Medical University of Gdańsk.Antibiotics (Basel, Switzerland) · 2021Article
- Drug-Induced Photosensitivity-From Light and Chemistry to Biological Reactions and Clinical Symptoms.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis.Cureus · 2021Article
- Antibiotics: Conventional Therapy and Natural Compounds with Antibacterial Activity-A Pharmaco-Toxicological Screening.Antibiotics (Basel, Switzerland) · 2021Review
- Molecular and Biochemical Basis of Minocycline-Induced Hyperpigmentation-The Study on Normal Human Melanocytes Exposed to UVA and UVB Radiation.International journal of molecular sciences · 2021Article
- Dermoscopic Aspects of Cutaneous Adverse Drug Reactions.Dermatology practical & conceptual · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In everyday clinical practice, almost all physicians come across many instances of suspected adverse cutaneous drug reactions (ACDR) in different forms. Although such cutaneous reactions are common, comprehensive information regarding their incidence, severity and ultimate health effects are often not available as many cases go unreported. It is also a fact that in the present world, almost everyday a new drug enters market; therefore, a chance of a new drug reaction manifesting somewhere in some form in any corner of world is unknown or unreported. Although many a times, presentation is too trivial and benign, the early identification of the condition and identifying the culprit drug and omit it at earliest holds the keystone in management and prevention of a more severe drug rash. Therefore, not only the dermatologists, but all practicing physicians should be familiar with these conditions to diagnose them early and to be prepared to handle them adequately. However, we all know it is most challenging and practically difficult when patient is on multiple medicines because of myriad clinical symptoms, poorly understood multiple mechanisms of drug-host interaction, relative paucity of laboratory testing that is available for any definitive and confirmatory drug-specific testing. Therefore, in practice, the diagnosis of ACDR is purely based on clinical judgment. In this discussion, we will be primarily focusing on pathomechanism and approach to reach a diagnosis, which is the vital pillar to manage any case of ACDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.